Johnson & Johnson

Valuation Analysis

About the Company

Johnson & Johnson en bref

Johnson & Johnson (JNJ) is currently trading at 199,41 € with a market capitalization of 480,0 Md €. The trailing P/E ratio stands at 26.48x, with a forward P/E of 17.97x. The 52-week range spans from 130,06 € to 219,66 €; the current price is 9.2% below the yearly high. Year-over-year revenue growth stands at +9.9%. The net profit margin stands at 21.83%.

💰 Dividende

Johnson & Johnson currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

23 analystes évaluent Johnson & Johnson (JNJ) au consensus : Acheter. L'objectif de cours moyen est de 220,67 €, soit un potentiel de +10.66% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 135,26 € à 248,71 €.

Johnson & Johnson : la thèse d'investissement en détail

Johnson & Johnson (JNJ) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 68.04%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 26.42% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 21.83%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Valorisation en contexte

At a PEG of 3.06, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 17.97x is meaningfully below the trailing 26.48x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Johnson & Johnson?

Compare top-rated brokers — low fees, trusted providers, fully regulated.